SparingVision

Stephane Boissel, CEO
Paris, France
(Private)
SparingVision is a biotechnology company focused on the discovery and development of innovative therapies for the treatment of blinding inherited retinal diseases. SparingVision is developing SPVN06, a gene-independent treatment for retinitis pigmentosa, the most common inherited retinal degeneration. There is currently no treatment to treat all genetic forms of this rare retinal disease that leads to blindness and affects nearly two million people worldwide. www.sparingvision.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions